EXHIBIT 99.01

                    Cellegy Withdraws NDA for Cellegesic(TM)

South  San  Francisco,  CA - April  26,  2002 -  Cellegy  Pharmaceuticals,  Inc.
(Nasdaq:  CLGY) announced  today that it has withdrawn its New Drug  Application
("NDA") for  Cellegesic(TM)  (nitroglycerin  ointment) for the treatment of pain
associated with chronic anal fissures.  The decision to withdraw the application
follows a recent  meeting  with the FDA  during  which it became  clear that the
Agency  would  require  additional  information  in  order  to  grant  marketing
clearance of Cellegesic in the United  States.  The  Cellegesic NDA was filed on
June 26, 2001.

Cellegy was disappointed by the FDA's position and believes that it has provided
evidence  sufficient for the approval of Cellegesic.  Nevertheless,  the company
has  decided  to  withdraw  its NDA and to work  cooperatively  with  the FDA in
providing  additional  information that will satisfy the Agency. Such additional
information may be in the form of supplemental data from completed  studies,  or
it may take the form of additional  clinical studies.  The company plans to meet
again soon with the FDA in order to obtain  agreement on the type of  additional
information needed.

"We have a positive  relationship  with the FDA and they have expressed a desire
to work  collaboratively with us in addressing their issues," said Dan Azarnoff,
Senior Vice President,  Clinical and Regulatory Affairs.  "We are confident that
Cellegesic  is an  effective  and  well-tolerated  product for the  treatment of
chronic anal fissure pain."

You are invited to participate in Cellegy's conference call scheduled for today,
April 26, 2002,  at 8:00 a.m.  PST to discuss the subject of this press  release
and the company's outlook. United States/Canada:  (877) 697-5170; International:
(706) 634-1522.

Cellegy Pharmaceuticals is a specialty  biopharmaceutical company focused on the
areas of  gastroenterology,  the  treatment of sexual  dysfunction  in males and
females and the treatment of selected women's health disorders.

This press release contains forward-looking statements that are made pursuant to
the safe harbor  provisions  of the  Securities  Litigation  Reform Act of 1995.
Investors should be aware that these  forward-looking  statements are subject to
risks and uncertainties, known and unknown, which could cause actual results and
developments  to differ  materially  from  those  expressed  or  implied in such
statements.  Such risks and  uncertainties  relate to, among other factors:  the
completion and outcome of clinical  trials;  the outcome and timing of review by
the FDA and other  regulatory  authorities;  our need for further  financing and
ability to complete potential financings; and various uncertainties arising from
the withdrawal of our NDA relating to Cellegesic. There can be no assurance that
Cellegy's  products will be approved for marketing by regulatory  authorities or
will be



                                    - more -

successfully  marketed following approval.  You are cautioned not to place undue
reliance on forward-looking  statements and we undertake no obligation to update
or revise statements made herein. For more information  regarding the above, and
other risk factors that may affect Cellegy's future results and may cause actual
results  to  vary  from  results  anticipated  in  forward-looking   statements,
investors  should refer to the company's Annual Report on Form 10-K for the year
ended  December  31, 2001 and other  documents  that the company  files with the
Securities and Exchange Commission, which are available online at www.sec.gov or
by contacting the company.